reviewJNCI Journal of the National Cancer InstituteDec 11, 2009GREEN OA

Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention

AAAdriana AlbiniGPGiuseppina PennesiFDFrancesco DonatelliRCRosaria CammarotaSDSilvio De Flora

MultiMedica · Istituti di Ricovero e Cura a Carattere Scientifico · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Due to the aging of the populations of developed countries and a common occurrence of risk factors, it is increasingly probable that a patient may have both cancer and cardiovascular disease. In addition, cytotoxic agents and targeted therapies used to treat cancer, including classic chemotherapeutic agents, monoclonal antibodies that target tyrosine kinase receptors, small molecule tyrosine kinase inhibitors, and even antiangiogenic drugs and chemoprevention agents such as cyclooxygenase-2 inhibitors, all affect the cardiovascular system. One of the reasons is that many agents reach targets in the microenvironment and do not affect only the tumor. Combination therapy often amplifies cardiotoxicity, and…

Citation impact

838
total citations
FWCI
22.16
Percentile
100%
References
139
Citations per year

Authors

6

Topics & keywords

Topics
Keywords
  • Cardiotoxicity
  • Medicine
  • Cancer
  • Intensive care medicine
  • Adverse effect
  • Disease
  • Radiation therapy
  • Oncology
UN Sustainable Development Goals
  • Partnerships for the goals
No related works found for this paper.

Funding